The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Azacitidine/HDAC inhibitor combination for high risk AML: a promising pilot study
For high-risk acute myeloid leukemia (AML), azacitidine monotherapy is typically utilized. However, there is a low overall response rate and relapse typically follows. In this interview, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the promising results of the Phase I/II ROMAZA study (ISRCTN69211255), which combines azacitadine with the histone deacetylase inhibitor romidepsin. Prof. Craddocks highlights the scalability of the results of this study moving forwards. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
